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Abstract. Identification of germline mutations in the RET proto-oncogene
predisposing to multiple endocrine neoplasia type IIa (MEN-IIa) has
allowed a DNA-based approach to diagnosis and treatment by prophy-
lactic thyroidectomy in children testing genetically positive. Although
total thyroidectomy is the accepted operation for C cell disease, the
necessity of routine total parathyroidectomy and autotransplantation as
previously described in these asymptomatic children is questionable,
particularly given the low occurrence of hyperparathyroidism in MEN-IIa
(10–20%). Thirty-six children (ages 1 month to 12 years) from four
MEN-IIa kindreds at risk for disease underwent genetic testing. Muta-
tional analysis was done using a highly sensitive PCR-based denaturing
gradient gel electrophoresis technique. Parathyroid or serum calcium
concentrations were determined preoperatively. Of the 36 children at risk,
18 were found to have a MEN-IIa mutation; 11 have undergone prophy-
lactic thyroidectomy at ages ranging from 2 to 12 years (mean 7.5 years).
In each case, there was no biochemical evidence of hypercalcemia
preoperatively, and all parathyroid glands were identified and were found
to be grossly normal at exploration. Glands were carefully dissected and
left in situ. Postoperatively, 10 of the 11 children maintained normocal-
cemia, allowing discharge within 24 to 36 hours. Resected thyroid glands
contained C cell hyperplasia in nine, medullary carcinoma in one, and
normal histology in one. We conclude that an alternative to routine
parathyroidectomy may be desirable for prophylactic treatment of MEN-
IIa. In situ parathyroid preservation can be safely achieved without
compromising the completeness of the thyroid resection. This conserva-
tive approach obviates the potential morbidity associated with total
parathyroidectomy and autotransplantation.
Germline missense mutations responsible for hereditary medul-
lary thyroid carcinoma (MTC) in the autosomal dominant cancer
syndromes, multiple endocrine neoplasia type IIa (MEN-IIa) and
familial medullary thyroid carcinoma (FMTC) have been identi-
fied within the coding region of the RET proto-oncogene, a
putative receptor tyrosine kinase [1, 2]. Penetrance of MTC in
MEN-IIa is essentially 100%, whereas expression of adrenal gland
pheochromocytoma and hyperparathyroidism (HPT) is more vari-
able, and congenital aganglionosis (Hirschsprung’s disease) is a
rare event [3, 4]. FMTC, a phenotypic variant of MEN-IIa, is
characterized by MTC alone. To date, the described mutations
predisposing to MEN-IIa involve single base changes at one of six
highly conserved cysteines within the extracellular domain of RET
at codons 609, 611, 618, 620, and 634 within exons 10 and 11 [1, 2,
5–7]. More recently, missense mutations affecting the tyrosine
catalytic domain in RET exons 13 and 14 at codons 768 and 804
have been reported to segregate with disease in several FMTC
kindreds [8, 9]. Overall, RET mutations have been identified in
approximately 97% of patients with MEN-IIa and 86% of FMTC
kindreds [10].
Identification of the genetic alterations predisposing to MEN-
IIa has allowed a DNA-based strategy for direct mutation detec-
tion and diagnosis in patients at risk [11]. The value of this
approach is readily apparent. Previously, screening for occult
hereditary MTC was accomplished biochemically by detecting an
elevation in the basal or pentagastrin-stimulated calcitonin con-
centration. This approach, although highly sensitive, had several
limitations. First, due to age-dependent biochemical penetrance
of the C cell abnormality, annual testing until 30 years of age was
necessary to safely exclude an affected status. Second, unpleasant
side effects produced by the pentagastrin injection and high cost
of the calcitonin assaying hindered compliance with family eval-
uation. Furthermore, calcitonin screening of all first-degree rela-
tives in index MTC cases was cumbersome and difficult to
accomplish. Finally, as we have shown, calcitonin testing appears
to lack specificity with exaggerated responses occurring in normal
subjects [11]. This has led in the past to unnecessary thyroid
operations and disease surveillance. In contrast, diagnosis of
MEN-IIa and FMTC by direct mutation detection is highly
sensitive, absolutely specific, and definitive. Therefore genetic
screening need only be performed on a single occasion to
determine susceptibility to MEN-IIa/FMTC with adverse effects
confined to that of a simple peripheral blood draw.
Because MTC is essentially 100% penetrant in MEN-IIa,
prophylactic total thyroidectomy is the accepted operation in
children testing genetically positive and, given the natural history
of the disease, can be readily justified despite normal calcitonin
findings. A recent study has also described the routine use of total
parathyroidectomy and forearm autotransplantation in asymp-
tomatic children with genetically proved MEN-IIa [12]. However,
a more conservative and alternative approach such as in situ
parathyroid gland preservation in these young patients with-
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out evidence of hyperparathyroidism might be considered for
three reasons. First, unlike the adrenal chromaffin and thyroid C
cell abnormalities, the incidence of parathyroid disease in MEN-
IIa is low, occurring in only approximately 10% to 20% of patients
[13, 14]. Second, the parathyroid gland involvement in MEN-IIa,
if present, has been shown not to be multifocal [3, 13, 14]. Finally,
recent MEN-IIa phenotype-genotype correlation studies suggest
that predisposition to hyperparathyroidism is not uniform among
the MEN-IIa RET mutations; rather, it is most tightly linked to
the CGCArg mutation at codon 634 in exon 11 [10]. Therefore
aggressive resection of all four parathyroid glands appears unnec-
essary in most cases. The purpose of this report is to describe our
success with an alternative, less radical approach to the operative
management of MEN-IIa following DNA diagnosis that can be
considered for children undergoing prophylactic treatment.
Patients and Methods
Patient Population
Fifteen male and 21 female patients (ages 1 month to 12 years)
from four distinct, well characterized, multigenerational MEN-IIa
kindreds at direct risk for disease underwent mutational analysis.
Two of the four kindreds from which eight of the children are
derived have been previously described by our group in greater
detail [3, 15]. The risk of MEN-IIa in each child was recognized
following genetic and histologic confirmation of an affected status
in a parent. Informed parental consent was obtained prior to
blood sampling and mutational analysis in each case.
Mutational Analysis of RET Exons 10 and 11
Polymerase chain reaction (PCR) amplification of RET exons 10
and 11 and denaturing gradient gel electrophoresis (DGGE) was
performed on genomic DNA extracted from the peripheral blood
leukocytes using established experimental conditions developed in
our laboratory [16]. Independent blood sampling was performed
in each case on two occasions. Primers 59GCGCCCCCCGC-
CCCCGCCCCGCCCGCCGCGGCGCCCCAGGAGGT-
GAGTG 39 (59 primer) and 59CGTGGTGGTCCCGGCCGCC39
(39 primer) were selected from intronic sequence flanking the
intron/exon boundaries of exon 10 following MELT87 analysis
[17]. Amplification of the 216 basepair (bp) fragment was per-
formed using 1 mg genomic DNA template, 2.2 mM each oligo-
nucleotide primer, 200 mM each dNTP, 1.25 U Taq DNA
polymerase (Gibco BRL, Gaithersburg, MD, USA). 10 mM Tris
(pH 8.3), 50 mM KCl, 2.0 mM MgCl2 in a total volume of 50 ml.
Thermal cycling conditions consisted of 35 cycles at 958C for 1
minute (denaturation) and at 728C for 1 minute (annealing and
extension).
Exon11primers,59CCTCACACCACCCCCACCCA39 (59prim-
er) and 59(GC)15GTCCAGCGAGGGCCGGCGGG39 (39 prim-
er) flanking Cys codon 634 were chosen following MELT87
analysis. Amplification was performed using 1 mg genomic DNA,
2.2 mM each primer, 200 mM dNTP, 1.25 units Taq polymerase, 10
mM Tris (pH 8.3), 50 mM KCl, 1.5 mM MgCl2, and 10% DMSO
in a final volume of 50 ml. Expected product size is 268 bp.
Conditions for amplification consisted of 35 cycles of denaturation
at 958C for 1 minute (denaturation), annealing at 628C for 30
seconds, and extension at 728C for 1 minute. Following each
amplification, samples were heated to 1008C for 10 minutes and
allowed to cool to room temperature prior to gel loading to
facilitate heteroduplex formation.
The DGGE analysis was carried out on a 1 mm thick 9%
acrylamide gel (acrylamide:bis-acrylamide 20:1) with a 50% to
80% linear gradient of denaturants (100% 5 7 M urea, 40% (v/v)
formamide) in 13TAE buffer (40 mM Tris acetate, 20 mM
sodium acetate, 1 mM EDTA at pH 7.8). Gel was overlayed with
a 6% polyacrylamide stacker (acrylamide:bis-acrylamide 30:1)
containing 13TAE. Amplified PCR fragments were electropho-
resed at 658C and 17 mA/gel for 18 hours (Hoefer Scientific
Instruments, San Francisco, CA, USA), with recirculation of
buffer from the lower to the upper electrode chamber, and
ethidium bromide-stained (10 minutes) prior to visualization. Per
laboratory protocol, initial genetic testing results are routinely
confirmed by a second, identical analysis.
Physical Examination and Biochemical Studies
Examination of the neck in the 36 children was unremarkable. All
children testing genetically positive scheduled for immediate
thyroidectomy were evaluated biochemically for asymptomatic
hyperparathyroidism with parathyroid hormone (intact), serum
calcium determinations, or both preoperatively. Fasting baseline
calcitonin sampling was considered optional and was performed in
only 8 of the 11 children. To date, 6 of the 11 children have
undergone pentagastrin stimulation testing immediately following
thyroidectomy. Provocative testing consisted of the intravenous
administration of a pulse injection of pentagastrin (Peptavlon,
Ayerst, NY, USA) at the conventional dose of 0.5 mg/kg. Patients
were evaluated in the fasting state, and blood was collected from
an antecubital vein before and at 1, 2, and 5 minutes after the test
agent was administered. Calcitonin levels were determined using
a commercially available radioimmunoassay (Nichols Institute,
San Juan Capistrano, CA, USA). Postoperative serum calcium
levels were routinely documented the evening and morning after
thyroidectomy.
Results
Genetic, biochemical, and histologic findings for each child are
summarized in Table 1.
DNA Analysis of RET
Of the 36 children at risk for disease, 18 were found to have a
MEN-IIa mutation. Of the 18, 11 (age range 2–12 years; mean
7.5) found to be genetically positive underwent immediate thy-
roidectomy. Within the group of 11 children undergoing immedi-
ate operative treatment, DGGE identified an abnormal multiple
banding pattern in exon 10 of the RET proto-oncogene in all
cases. Germline RET mutations consistent with MEN-IIa were
detected at Cys codons 618 (TGC 3 AGC) and 620 (TGC 3
CGC, TGC 3 TGG) and confirmed by direct DNA sequencing
(Fig. 1). An example of the DGGE analysis of a MEN-IIa kindred
with the Cys codon 620 TGG mutation is shown in Figure 2. The
multiple banding pattern reflective of a heterozygous missense
change is clearly present in all family members affected with the
disease. Unaffected individuals exhibit a single band resulting
from normal homozygous sequence.
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Biochemical Testing
There was no biochemical evidence of hypercalcemia in any of the
11 children. Two patients had an elevated parathyroid hormone
(PTH) concentration despite a normal serum calcium determina-
tion. Preoperative baseline peripheral calcitonin levels were all
within the ranges of normal (females ,17 pg/ml; males ,26
pg/ml) in each case. Postoperative baseline and stimulated calci-
tonin levels were normal in each of the six children tested to date.
Operative Strategy and Histologic Findings
All 11 children underwent a total thyroidectomy performed
according to the method of Crile. During the operation, resected
thyroid glands were thoroughly palpated and meticulously sec-
tioned vertically and horizontally in search of gross, macroscopic
MTC with particular attention directed to the upper two-thirds
poles of each lobe, posteriorly. In each case, gross disease in the
thyroid or central nodal compartment was not present, and
therefore central dissections for occult metastases were deemed
unnecessary. Upon histopathologic examination of the thyroid
specimen, nine children had C cell hyperplasia (CCH), one child
(age 12 years) had medullary carcinoma, and the remaining
patient (age 4 years) had normal microscopic findings. In three
cases, detailed sectioning and immunohistochemical staining of
the gland for calcitonin was required to identify the abnormal
focus. All cases were independently reviewed by two pathologists
at separate institutions. Identified parathyroid glands were grossly
unremarkable in all of the children (including the two patients
with an elevated PTH preoperatively) and therefore carefully
dissected for in situ preservation. A parathyroid biopsy was done
on three glands intraoperatively to confirm their identification. All
were histologically normal. Two children underwent transplanta-
tion of a single parathyroid gland into a sternocleidomastoid
muscle.
Postoperative Course
Of the 11 children, 10 maintained normocalcemia throughout
their operative course. A single child, age 9 years, required
transient calcium and vitamin D replacement. Of the 10 children
with a normal calcium, 5 were discharged within 24 hours after
operation. Early discharge in the remaining 5 patients was com-
promised by postanesthesia nausea and vomiting, which pro-
longed hospitalization up to 36 hours. There were no wound or
recurrent nerve complications.
Table 1. Children undergoing prophylactic thyroidectomy after RET


















1/F 2 9.7/9.5 82 13.8 c620CGC CCH
2/M 4 9.0/8.9 27 ND c618AGC Normal
3/F 5 10.2/9.7 22 ND c618AGC CCH
4/F 5 9.4/9.6 36 13.0 c618AGC CCH
5/M 6 10.2/9.4 ND 13.0 c618AGC CCH
6/M 9 9.4/9.6 32 13.9 c620TGG CCH
7/F 9 9.4/7.9 86 ND c618AGC CCH
8/F 10 9.6/9.0 38 13.0 c618AGC CCH
9/F 10 9.3/9.1 27 ND c618AGC CCH
10/M 11 9.6/9.7 20 6.8 c620TGG CCH
11/F 12 10.0/9.4 34 17.0 c618AGC MTC
PTH, serum parathyroid hormone (intact); ND, not done; CCH, C
cell hyperplasia; MTC, medullary thyroid carcinoma.
Fig. 1. DGGE analysis of PCR-amplified fragments representing the 3
RET mutations occurring among the 11 children at Cys codons 618 and
620 in exon 10 of the RET proto-oncogene with normal sequenced
controls. Single base substitution and corresponding codon relative to the
RET coding sequence are as indicated. Codons are numbered from the
transcription start site as defined by Kwok et al. [19] and Itoh et al. [18]
Note the unique and clearly distinguishable banding pattern for each
mutation and high resolving power of the DGGE mutation detection
system.
Fig. 2. Pedigree and DGGE gel analysis of RET exon 10 from a family
with MEN-IIa. Closed symbols indicate patients with MEN-IIa. Unaf-
fected individuals are indicated by the open symbols. Note the multiple
banding pattern in affected members, reflecting the heterozygous missense
change. Unaffected subjects show a single band, representing homozygous,
wild-type sequence. Direct DNA sequencing (not shown) revealed a TGC
3 TGG base substitution at nucleotide 2055, a previously unreported
MEN-IIa mutation. Arrowheads, children undergoing prophylactic thy-
roidectomy following genetic diagnosis.
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Discussion
The RET proto-oncogene encodes a 1114 amino acid protein
resembling a transmembrane receptor with tyrosine kinase activity
[18, 19]. Structurally, the protein consists of a signal sequence, an
extracellular domain harboring a cysteine-rich region and se-
quence homologous to the cadherins, a hydrophobic transmem-
brane domain, and an intracellular tyrosine kinase domain. It is
predicted that RET encodes a receptor for a presently unknown
growth factor ligand. Transcription of c-RET mRNA is found in
normal human thyroid C cells [20] and preferentially in tumors
derived from neural crest, including the MEN-II tumors, MTC,
and pheochromocytoma [21, 22]. The parathyroid gland, also
affected in MEN-IIa, is not a neural crest derivative but arises
from the endoderm of the posterior branchial arches, which
strongly express RET during embryogenesis [23]. It provides the
common developmental link between the thyroid, adrenal, and
parathyroid tissues involved in MEN-IIa.
Parathyroid disease occurs in approximately 10% to 20% of
patients with MEN-IIa [3, 13, 14]. Unlike the HPT of MEN type
I (MEN-I), however, parathyroid disease when present in MEN-
IIa tends not to involve all four glands. Therefore adequate
treatment has traditionally been achieved by resection limited to
the abnormally enlarged gland(s). The basis for the highly variable
expression of HPT in the MEN-IIa syndrome between kindreds is
unknown (vide infra). To date, parathyroid disease has been
documented in two of the four MEN-IIa kindreds in this study at
low incidences of 12% and 4%, respectively. The PTH elevation in
two of the children preoperatively remains unexplained, as there
was no biochemical evidence of hypercalcemia or grossly enlarged
parathyroid glands by careful inspection in either case. Therefore
parathyroid resection was deemed unwarranted, and routine
parathyroid biopsy of macroscopically unremarkable glands was
not performed in any of the children as to avoid iatrogenic
hypoparathyroidism. Likewise, in a report by Wells and colleagues
[12] there was no indication of parathyroid pathology in 13
genetically positive children, although treatment consisted of total
parathyroidectomy and autotransplantation. Furthermore, we [3]
and others [13] have shown in previous studies that children
subjected to early thyroidectomy as a result of prospective (pen-
tagastrin) screening for CCH showed no evidence of parathyroid
hyperplasia at the time of thyroid operation or during a follow-up
period of 10 years. For these reasons, it seems that parathyroid
gland preservation, rather than resection, is appropriate and
sufficient for children undergoing prophylactic treatment for
MEN-IIa.
An initial study correlating RET genotype and disease pheno-
type in 54 MEN-IIa families with diverse mutations suggests that
the CGC mutation at codon 634 in exon 11, which produces a
cysteine to arginine amino acid substitution, is strongly predictive
of parathyroid disease (p 5 0.000008) [10]. Mulligan et al. [10]
reported a high incidence (73%) of families with MTC and
parathyroid disease specifically had the TGC3GCG mutation at
codon 634. The basis of this specificity is unknown but may reflect
a variance in sensitivity to the dosage of RET required to trigger
hyperplasia in the respective C cell, adrenal, and parathyroid
tissues. Obviously, although RET expression studies are needed to
examine this model, it may be that any MEN-IIa RET mutation is
sufficient to induce CCH in the thyroid gland, whereas a higher
threshold and level of RET expression, as possibly conferred by
Cys634Arg mutation, is necessary to affect the parathyroid cell.
However, the correlation between this mutation and parathyroid
involvement is not absolute, and therefore all patients with
hereditary MTC regardless of RET genotype must be screened
annually for hyperparathyroidism (HPT). Furthermore, the pres-
ence of the CGC c634 genotype segregating within a family cannot
predict the occurrence of parathyroid disease in any given affected
member. For these reasons, it appears that the genetics of HPT in
MEN-IIa is more complex than that of the C cell disease; and an
individualized, rather than uniform, approach to operative man-
agement of the parathyroid glands is indicated. None of the 11
children in the present study had the CGC c634 mutation.
Clarification of whether young children with the c634 genotype
are ultimately at a greater risk for harboring or developing
parathyroid adenomas following prophylactic thyroidectomy
awaits dedicated studies of this patient subgroup.
It may be argued that total parathyroidectomy and autotrans-
plantation are routinely necessary to ensure adequacy of the
central compartment dissection in these young children. However,
operative strategies employed to deal with possible nodal spread
cannot by definition be designated “prophylactic” and should not
be recommended in the asymptomatic setting. Young children
with MEN-IIa predicted to have histologically normal thyroid
glands or premalignant CCH do not require nodal explorations
with the attendent potential morbidity. More extensive dissections
should be reserved for patients with evidence of macroscopic
thyroid tumor or obvious nodal metastases. The oldest of the 11
children in this series (age 12 years) had histologic evidence of
malignant conversion to microscopic MTC and therefore in the
strictest sense had surpassed “prophylactic” treatment. Postoper-
ative stimulated calcitonin levels at 30 months remain undetect-
able. Fortunately, the capability to diagnose MEN-IIa genetically
should allow earlier thyroid resection, prior to the development of
any biochemical and histologic abnormalities.
Our current strategy for the management of the thyroid C cell
disease and parathyroids in patients at risk for MEN-IIa is shown
in Figure 3. This approach is cost-effective and results in the least
morbidity to patients. As indicated, DNA analysis by direct
mutation detection using DGGE is the first-line diagnostic tool
for evaluating MEN-IIa and performed in lieu of conventional
calcitonin screening. Overall, given the autosomal dominant na-
Fig. 3. Management of patients with MEN-IIa after genetic diagnosis
(see text).
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ture of disease transmission, it can be anticipated that approxi-
mately one-half of the biologic children from an affected parent
will have the mutation, males and females being equally predis-
posed. Because of the predictive power and high resolution of our
DGGE technique, patients who do not carry a RET mutation are
confidently excluded, along with their descendants, from the
screening process without any further evaluation. Management of
those individuals testing genetically positive is determined by age,
manner of presentation, and gross findings of the thyroid and
parathyroid glands at the time of operation. Generally, asymp-
tomatic children can undergo thyroid operation without biochem-
ical evaluation of their C cell abnormality, and we have therefore
abandoned preoperative pentagastrin screening. At surgery, the
resected thyroid specimen is carefully sectioned and inspected for
macroscopic tumor (understanding that the disease may be of
millimeter size). If present, a central compartment dissection for
occult nodal disease including thymectomy is considered. If
absent, operation is limited to a total thyroidectomy. In this study,
macroscopic disease was not present in any of the 11 children, and
therefore operation consisted in thyroid resection alone.
Parathyroid activity is routinely determined preoperatively in
all patients including young children by measuring PTH, serum
calcium, or both. A normal calcium value obviates the need to
search exhaustively for all four parathyroid glands if they cannot
be readily identified without extensive dissection. In this scenario,
parathyroid resection with transplantation to a sternocleidomas-
toid rather than forearm muscle is performed and is reserved for
those cases in which the vascular supply to a normal gland appears
tenuous. Parathyroid glands preserved in situ may be tagged with
metal clips to indicate their location.
Given the age-dependent penetrance of MTC in MEN-II, older
children and adults who are genetically positive are at risk for
more advanced disease. Therefore a fasting baseline calcitonin
level is determined in these groups to assess tumor bulk and the
need for a metastatic evaluation as well as to plan operative
strategy. However, at no time has calcitonin testing been under-
taken to confirm results of our DNA analysis. Of course, biochem-
ical screening must continue in the few patients at risk for
MEN-IIa from clearly established families in whom the RET
mutation has not yet been identified.
We have initiated genetic screening in children as early as
infancy. Early diagnosis allows parents to plan for timely, elective
(prophylactic) operation and relieves them of undue concern for
children found to be nongene carriers. It is our recommendation
that total thyroidectomy be undertaken by age 5 years in children
who have a MEN-IIa RETmutation. The results of this study have
shown that CCH is present as early as 2 years of age, and indeed
MTC has been reported in a child with MEN-IIa at age 2.8 years
[24]. Others have suggested that provocative pentagastrin screen-
ing be continued in children testing genetically positive so as to
defer operation until the age of biochemical conversion [25].
Proponents of this strategy maintain that thyroidectomy is better
tolerated and technically easier in the older child or adolescent.
We do not espouse this approach as it does not alter the
inevitability of operative treatment and contributes unnecessarily
to patient morbidity, parental anxiety, and medical costs. Indeed,
it has been our experience that children as young as 2 years of age
can undergo thyroidectomy with no complications and far less
subjective trauma than do adolescents. Moreover, thyroidectomy
in the young child is no more technically challenging than in the
adult, especially in the hands of an experienced thyroid surgeon.
Furthermore, early thyroid operation is more likely to be truly
“prophylactic” in nature and curative. Finally, there appears to be
an overlap in the absolute calcitonin levels, which correspond to
disease progression from CCH to MTC and vary with the
calcitonin assaying system employed. This situation further in-
creases the uncertainty and risks involved with postponing defin-
itive surgery until more impressive and “definitive” biochemical
abnormalities are realized.
As shown in the current study, early operation after genetic
diagnosis alone occasionally results in removal of histologically
normal thyroid glands. This possibility should be anticipated and
considered desirable for the operative treatment initiated for
prophylaxis, as the age of disease onset (penetrance) varies in
children. Unremarkable histology occurred in a single child in this
study age 4 years with Hirschsprung’s disease, a phenotypic
marker of MEN-IIa that supported the genetic findings. In three
children, detailed sectioning of the gland and immunohistochem-
ical staining for calcitonin were required to uncover the disease
focus, attesting to the importance of careful specimen sampling
and the greater sensitivity of genetic testing for detecting an
affected status. Various DNA-based techniques have emerged to
identify RET mutations. Unlike other methods, the DGGE ap-
proach we have employed has been acknowledged by others as
capable of detecting virtually 100% of mutations [26, 27]. Abnor-
mal findings identified by DGGE are routinely confirmed by
direct DNA sequencing and restriction fragment length polymor-
phism (RFLP) analysis. Discordance between results has not been
observed.
The frequency of postoperative follow-up screening by calcito-
nin testing in children undergoing preventive thyroidectomy is not
yet defined, although intuitively it will be less stringent than that
for macroscopic disease. If completeness of the thyroid resection
can be ensured, “recurrence” of MTC following removal of a
gland containing the premalignant CCH alone or normal histol-
ogy would be unexpected. Of course, lifelong biochemical surveil-
lance for development of HPT or adrenal pheochromocytoma
regardless of the RET genotype is indicated.
In conclusion, routine parathyroidectomy during prophylactic
thyroidectomy in children with MEN-IIa does not appear neces-
sary. Long-term follow-up studies are needed to better determine
the occurrence of HPT after preventive surgery prior to recom-
mending a radical approach, such as four-gland resection and
heterotopic reimplantation. It appears that more conservative
measures are desirable in these young children to minimize any
potential morbidity with prophylactic thyroidectomy, including
that associated with total parathyroidectomy and autotransplan-
tation.
Résumé
L’identification de la mutation germline dans le proto-oncogène
RET, prédisposant au syndrome de néoplasie endocrine multiple
(MEN) 2a, permet une approche diagnostique basée sur l’étude
de l’ADN et il peut être proposé alors une thyroı̈dectomie à titre
prophylactique chez l’enfant génétiquement positif. Bien que la
thyroı̈dectomie totale soit le traitement de choix pour la maladie
des cellules C, la nécessité d’y associer une parathyroı̈dectomie
totale systématique suivie d’autotransplantation, déjà décrite chez
les enfants asymptomatiques, est tout à fait discutable, compte
818 World J. Surg. Vol. 20, No. 7, September 1996
tenu de la prévalence basse de l’hyperparathyroı̈die dans le MEN
2a (10–20%). Trente-six enfants à risque pour la maladie car
faisant partie de la proche famille de quatre patients MEN 2a
(âgés de 1 mois à 12 ans), ont eu une analyse mutationelle,
réalisée par la technique d’électrophorèse sur gel dénaturant
basée sur une PCR hypersensible. Les concentrations de calcium
dans la parathyroı̈de et/ou le sérum ont été déterminées en
préopératoire. On a trouvé la mutation MEN 2a chez 18 des 36
enfants à risque, dont 11 ont eu une thyroı̈dectomie à titre
prophylactique entre l’âge de 2 à 12 ans (moyenne 5 7.5 ans).
Dans chaque cas, il n’y avait aucune preuve biochimique
d’hypercalcémie en préopératoire. Toutes les glandes parathy-
roı̈des ont été identifiées et apparaissaient macroscopiquement
normales à l’exploration. Les glandes ont été disséquées et
laissées in situ. En postopératoire, on a maintenu la normocalcé-
mie chez 10 des 11 enfants, ce qui a permis de les laisser sortir de
l’hôpital entre 24–36 heures après l’opération. La thyroı̈de résé-
quée contenaient une hyperplasie des cellules C chez neuf, un
cancer médullaire chez un alors que l’histologie était normale
chez le dernier. Nous concluons qu’une alternative à la parathy-
roı̈dectomie systématique peut être proposée dans le traitement
prophylactique du syndrome MEN 2a. La conservation parathy-
roı̈dienne in situ peut être accomplie avec sécurité sans compro-
mettre le caractère complet de la résection de la thyroı̈de. Cette
approche conservatrice épargne le patient de la morbidité poten-
tielle associée à la parathyroı̈dectomie totale suivie de l’auto-
transplantation.
Resumen
La identificación de mutaciones en el proto-oncogen RET pre-
disponente de la neoplasia endocrina múltiple tipo 2a (NEM 2a)
ha permitido un aproche diagnóstico y terapéutico basado en
DNA mediante tiroidectomı́a profiláctica en niños que aparezcan
positivos en la prueba genética. Aunque la tiroidectomı́a total es
la operación aceptada para la enfermedad de células C, aparece
cuestionable la necesidad de paratiroidectomı́a total con auto
trasplante rutinario como ha sido previamente descrito en estos
niños asintomáticos, en especial si se tiene en cuenta la baja
incidencia de hiperparatiroidismo en el NEM-2a (10–20%).
Treinta y seis niños (edad 1 mes- 12 años) parientes de cuatro
pacientes con NEM-2a en riesgo de desarrollar la enfermedad
fueron sometidos a la prueba genética. Se practicó análisis
mutacional utilizando una técnica altamente sensible de electro-
foresis, se hicieron determinaciones preoperatorias de las concen-
traciones de hormona paratiroidea y/o calcio. Dieciocho de 36
niños en riesgo resultaron con la mutación NEM-2a, 11 de los
cuales han sido sometidos a tiroidectomı́a profiláctica a las edades
entre 2 y 12 años (media 7.5 años). En cada caso no hubo
evidencia preoperatoria de hipercalcemia y todas las paratiroides
fueron identificadas como macroscópicamente normales durante
la exploración operatoria. Las glándulas fueron cuidadosamente
identificadas y dejadas in situ. En el postoperatorio 10 de 11 niños
mantuvieron normocalcemia, lo cual permitió su egreso a las
24–36 horas. Las glándulas tiroides resecadas exhibieron hiper-
plasia de células C en 9 casos, carcinoma medular en 1 e histologı́a
normal en 1. Nuestra conclusión es que es deseable una alterna-
tiva a la paratiroidectomı́a rutinaria en el tratamiento profiláctico
del NEM-2a. La preservación paratiroidea in situ puede ser
lograda exitosamente sin comprometer la totalidad de la resección
tiroidea. Este aproche conservador evita la morbilidad asociada
con la paratiroidectomı́a total con autotrasplante.
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Invited Commentary
J.F. Moley, M.D.
Department of Surgery, Washington University School of Medicine, St.
Louis, Missouri, U.S.A.
Identification of RET gene mutations in patients at risk for the
development of the hereditary forms of medullary thyroid carci-
noma (MTC) has simplified management and expanded the scope
of indications for surgical intervention. Patients who carry this
mutation can be offered operation at a young age, hopefully at a
point when the cancer has not yet developed or spread. Those who
are found not to have inherited the mutation are spared further
genetic and biochemical screening. This achievement marks a new
paradigm in surgery—the recommendation that operation be
performed based on the result of a genetic test. As with the
decision to perform any surgical procedure, meticulous prepara-
tion and detailed discussion with the patient and family must
precede the final recommendation. At our institution, genetic
testing is repeated and confirmed on a separately drawn blood
sample, and the patient and family are involved in preoperative
discussions with genetic counselors as well as the surgical team.
This paper by Decker et al. adds to the growing number of
reports of surgical intervention in patients who have inherited a
multiple endocrine neoplasia (MEN) type IIa RET gene mutation.
In this contribution, the authors stress their approach to the
parathyroid glands. At the time of thyroidectomy, they biopsy and
mark each parathyroid gland with a surgical clip and leave the
glands in situ. This approach is similar to that reported by other
groups performing thyroidectomy in MEN-IIa gene carriers [1–3].
The approach contrasts with the practice at our institution, which
is to perform total thyroidectomy, central node dissection, and
total parathyroidectomy with autotransplantation of a portion of
the parathyroid tissue into the muscle of the nondominant
forearm, and viable freezing of the remaining tissue [4]. We
continue to prefer this approach for the following reasons. First,
patients with MEN-IIa are at risk for the development of hyper-
parathyroidism. If a patient subsequently develops hyperparathy-
roidism, localization of the hyperfunctioning tissue is simpler if
the parathyroid tissue is in the arm. Operation to reduce parathy-
roid tissue is carried out under local anesthesia as an outpatient,
obviating the risk of redo neck exploration. Decker et al. point out
that the overall incidence of hyperparathyroidism is low, and that
patient selection for parathyroidectomy might be guided by the
type of genetic mutation a patient has. At the present time, the
risk of hyperparathyroidism in patients with different RET gene
mutations is unclear. The Cys634Arg mutation was most strongly
associated with the presence of hyperparathyroidism in one study
correlating genotype with phenotype [5]. In that study, however,
criteria for diagnosis of hyperparathyroidism were not specified.
In addition, there was a preponderance of kindreds (24 of 54
evaluable kindreds) affected by a Cys634Arg mutation. Before
using genotype data to determine whether to transplant the
parathyroids, the data from this important initial study should be
confirmed by other groups. The risk of hyperparathyroidism in
MEN-IIa gene carriers following preventive thyroidectomy can
only be determined by follow-up over the lifetime of the patients.
Second, routine removal of the parathyroids ensures that an
adequate central node dissection can be done without jeopardiz-
ing parathyroid function. Decker and colleagues state that lymph
node metastasis is unlikely in patients who have inherited MEN-
IIa mutations who undergo preventive thyroidectomy. We have
found that metastases do occur in these patients. In our experi-
ence, histologic evidence of metastatic involvement of central
nodes was reported by the pathologists in 2 of 44 cases of
preventive thyroidectomy in MEN-IIa gene carriers. In one of
these patients there was no evidence of tumor on gross sectioning
of the gland. In addition, the fact that routine histologic exami-
nation (hematoxylin and eosin staining) fails to demonstrate
metastatic MTC does not exclude the possibility that occult foci
were removed. Of 50 patients with recurrent hypercalcitoninemia
after thyroidectomy with node removal for MTC followed by our
group, five patients had no histologic evidence of node involve-
ment at first operation. All five were found to have metastatic
involvement of residual neck nodes at an operation done years
later. In two patients from our series of patients with recurrent
hypercalcitoninemia following thyroidectomy for MTC, reopera-
tion with excision of cervical nodes resulted in marked reduction
in stimulated calcitonin levels even though routine pathologic
examination revealed no evidence of metastatic nodal involve-
ment. This suggests that in some cases metastatic foci may not be
detected by routine histologic examination.
Medullary thyroid cancer is an indolent disease, and recur-
rences may not be apparent for decades. The recurrence rate of
MTC following preventive thyroidectomy in MEN-IIa gene car-
riers is not known and will not be known until these patients have
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been followed for many years. Central node dissection is safe and
simple to perform; however, the parathyroids are closely associ-
ated with nodes draining the thyroid, and parathyroid blood
supply may be damaged in the process of removing these nodes.
Parathyroidectomy and autotransplantation ensures preservation
of parathyroid function.
In our series of 44 preventive thyroidectomies with central node
dissection in MEN-IIa gene carriers, parathyroidectomy with
autotransplantation has been carried out safely. In all patients,
there is evidence of good graft function, and only one patient
(who has a functioning autograft) still requires calcium supple-
mentation. We therefore continue to favor routine parathyroid-
ectomy and autotransplantation as a part of all primary operations
for MTC, including those done based on the result of a genetic
test, in a preventive setting.
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